These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12138498)

  • 1. Application of toxicogenomics to drug development.
    Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA
    Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of toxicogenomics.
    Waring JF; Halbert DN
    Curr Opin Mol Ther; 2002 Jun; 4(3):229-35. PubMed ID: 12139308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How molecular profiling could revolutionize drug discovery.
    Stoughton RB; Friend SH
    Nat Rev Drug Discov; 2005 Apr; 4(4):345-50. PubMed ID: 15789121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated expressional analysis: application to the drug discovery process.
    Ilyin SE; Horowitz D; Belkowski SM; Xin H; Eckardt AJ; Darrow AL; Chen C; Maley D; D'Andrea M; Plata-Salamán CR; Derian CK
    Methods; 2005 Nov; 37(3):280-8. PubMed ID: 16308157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive toxicogenomics in preclinical discovery.
    Barros SA; Martin RB
    Methods Mol Biol; 2008; 460():89-112. PubMed ID: 18449484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural proteomics in drug discovery.
    Tari LW; Rosenberg M; Schryvers AB
    Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in drug discovery and development: a translational perspective.
    Roses AD
    Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicogenomics in biomarker discovery.
    Decristofaro MF; Daniels KK
    Methods Mol Biol; 2008; 460():185-94. PubMed ID: 18449488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.